Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENACT: NAC in Asthma with Mucus Plugs
NCT03822637Phase 4Terminated
- Sponsor
- University of California, San Francisco
- Start
- Feb 2019
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of acetylcysteine in asthma (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Forced Expiratory Volume in 1 second at 9 weeks. Started Feb 2019; status: terminated.
02
Drugs
acetylcysteine
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03822637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822637.